Fosun Pharma

Long-term stock returns will be contingent on turnaround of the European acquisition and growth in US business

Gland Pharma shares worth Rs 1,815 cr sold in block deal; Fosun Pharma likely seller

According to reports, Fosun Pharma is expected to continue selling stakes in Gland Pharma over the coming months to strengthen its balance sheet unless buyout firms step in with an offer.

Fosun to sell 5% stake worth $172 mn in Gland Pharma via block deal

The block deal for Gland Pharma is likely to be launched at nearly 5 percent discount to the stock's current market price, showed the term sheet accessed by Moneycontrol.

Fosun said to mull sale of $3.6 Billion Gland Pharma

Fosun Pharma, a listed arm of Chinese conglomerate Fosun International Ltd., has been working with an adviser as it informally gauges interest in its controlling stake in Gland, the people said.

Fosun parentage yielding tangible benefits for Gland Pharma

Fosun reiterated its support for Gland Pharma in its latest investor update. It plans to help Gland Pharma expand in China

COVID-19 Vaccines | China’s Fosun Pharma signs deal for 1 billion vaccines with BioNTech

The vaccine has yet to be approved in mainland China, where regulations require an in-country clinical trial. BioNTech’s CEO has said the company expects the shot to be approved in July.

Fosun Pharma best fit due to global presence, size: Gland Pharma

Fosun Pharma complements the injectables platform created by Gland Pharma and provides scope to expand into front-end marketing, said Gland's Vice Chairman and Managing Director Ravi Penmetsa.